A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor

This study includes phase I dose escalation part and phase IIa dose expansion part. The goal of this clinical trial is to learn if C5252 treatment is safe and well tolerated in patients with intracranial tumor and to learn preliminary efficacy of C5252. In this study, participants will be given single or multiple doses of C5252 according to protocol followed by toxicity observation, safety follow-up and long-term follow-up.

NCT Number	NCT07243340
Lead Sponsor	ImmVira Pharma Co. Ltd
Conditions	Glioma, Malignant
Enrollment	36 participants
Start Date	2025-12-15
Primary Completion	2027-12-15 (estimated)
Study Completion	2028-12-15 (estimated)
Updated on ClinicalTrials.gov	2025-11-21